2023-02-14
Neratinib plus fulvestrant plus trastzuzumab is a promising combination for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (mBC): results from the phase II SUMMIT trial
There is a promising combination of neratinib plus fulvestrant plus trastzuzumab (N+F+T) to patients with HR+/HER2-/HER2mut metastatic breast cancer, who pretreated with CDK4/6 inhibitor.
1. Komal L. Jhaveri, Jonathan W. Goldman, et al. Journal of Clinical Oncology. 2022; 40, no. 16_suppl:1028-1028. 2. Eli LD, Kavuri SM. Cancer Drug Resist. 2022;5(4):873-881. 3. NCCN Clinical Practice Guidelines. Breast Cancer. Version 1.2023